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While optic neuritis (ON) is the archetypical first mode of presentation in multiple sclerosis (MS), its 
role in the diagnostic criteria remains surprisingly modest. Objective demonstration of an optic nerve 
lesion is not included in the McDonald criteria for the diagnosis of MS, even in the 2017 revisions, 
despite the serious consideration which was given to it by the International Panel, in association with 
the National Multiple Sclerosis Society and the European Committee for Treatment and Research in 
Multiple Sclerosis, when they recently met to revise the McDonald criteria [1]. The proposal to 
include optic nerve lesions in the diagnostic criteria was made by a European network, called 
MAGNIMS (magnetic resonance imaging in multiple sclerosis {www.magnims.eu}), to mirror their 
proposal [2] to treat symptomatic lesions in the brainstem and spinal cord similarly to asymptomatic 
lesions – a proposal that was included in the 2017 revisions [1]. The line of reasoning of the 
MAGNIMS group was that there was no fundamental reason to treat the (symptomatic) lesion in the 
optic nerve (such a classical site of involvement) differently than a brainstem or cord lesion [2]. 
In this issue of MSJ, the pros [3] and cons [4] of doing so are elaborated by debaters who, in the end, 
do not differ much in their conclusion. In the end their answers are “YES, but”, and “NOT, yet”. Such 
a paradox is a reflective of good science where the dialectics of arguments should stimulate both 
those who propose and refute the hypothesis to examine the evidence in favour and against it. In 
fact, both camps conclude that more data is needed for what essentially is a logical, next step for the 
next version of the McDonald criteria. 
The current evidence collected by the MAGNIMS group [5] was designated by the International Panel 
as too preliminary, despite showing a promising increase in sensitivity. The main concern of the panel 
was the reduced specificity, which may simply reflect the lack of long enough follow-up to ascertain 
late converters. However, even when all the abnormal cases do convert and specificity is good, it 
may signify a better prognosis for patients who present with ON and a few brain MRI lesions only [6]. 
Though not a diagnostic issue per se, this does convey a different prognosis and treatment 
implications. The discussion was muddied when going beyond MRI evidence as both camps agree 
that more standardization and normative data are needed for OCT and VEP. 
Essential data that are missing are a prospective study of all types of CIS patients (not just ON) with a 
systematic examination of the optic nerve, including MRI, OCT and VEP. Other issues that need to be 
addressed include standardization of these techniques, provision of normative data and 
differentiation from neuromyelitis optica (NMO). The MAGNIMS group has already embarked on 
such a study in Europe and hopefully others will contribute to the evidence base to give the optic 
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